Overview

• After a 2007–2014 drop of 6.4% per year, overall prostate cancer incidence rose 3.0% annually from 2014 to 2021, with advanced-stage diagnoses increasing about 4.6% to 4.8% per year.
• Mortality declines slowed to roughly 0.6% annually over the past decade based on national data through 2023.
• Distant-stage disease increased nearly 3% per year in men under 55 and about 6% per year in men 55 and older, with five‑year survival near 38% versus nearly 100% for localized cancer.
• Disparities persist as Black men face 67% higher incidence and about double the mortality of White men, and American Indian and Alaska Native men have higher death rates despite lower incidence, with the highest state rates in D.C. and Mississippi.
• ACS guidance calls for screening conversations at 50 for most men and at 45 for Black men or those with a family history, and its advocacy arm backs federal legislation to waive cost‑sharing for high‑risk screening as experts debate the impact of earlier USPSTF advice.